Pharmaceutical research company RiboTargets announces the appointment of Christopher Samler, currently chief executive of Weston Medical, as a non-executive director
Christopher Samler has been chief executive of Weston Medical, a drug delivery company, since June 1997.
Prior to this he served as CEO of Imutran, a Cambridge-based (UK) biotechnology firm. During his three year leadership, Mr Samler managed the successful sale and integration of Imutran with the Swiss pharmaceutical company, Novartis.
Mr.
Samler has also held senior positions with Baxter International where he latterly headed Bentley Laboratories, a European manufacturer of disposables for open-heart surgery.
Mr Samler, a former British Army officer, holds an MBA degree from Harvard Business School, USA, as well as a degree from Oxford University, UK.
Commenting on the appointment, Simon Sturge, Chief Executive of RiboTargets, said: "We are delighted that someone of Christopher's calibre has joined the Board of RiboTargets.
He has had considerable management experience at a number of leading healthcare and pharmaceutical companies which will be very valuable to RiboTargets as it expands its operations and development portfolio.
We look forward to working with him."
